These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18347149)

  • 1. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer.
    Vassileva V; Allen CJ; Piquette-Miller M
    Mol Cancer Ther; 2008 Mar; 7(3):630-7. PubMed ID: 18347149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
    Sui M; Chen F; Chen Z; Fan W
    Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The inhibitory effect of paclitaxel nanoparticles on ovarian cancer xenografts and lymphatic targeting].
    Lu HX; Xu CJ; Li B; Kang Y; Huang Q; Li LM; Chen QH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):483-6. PubMed ID: 17068619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 8. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR; Spencer CM
    Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
    Jain A; Jain SK
    Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
    Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
    Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly administration of paclitaxel: theoretical and clinical basis.
    Marchetti P; Urien S; Cappellini GA; Ronzino G; Ficorella C
    Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S3-13. PubMed ID: 12505595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors.
    Millenbaugh NJ; Gan Y; Au JL
    Pharm Res; 1998 Jan; 15(1):122-7. PubMed ID: 9487558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
    Ho EA; Soo PL; Allen C; Piquette-Miller M
    J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells.
    Pitchakarn P; Umsumarng S; Mapoung S; Ting P; Temviriyanukul P; Punfa W; Pompimon W; Limtrakul P
    J Nat Med; 2017 Oct; 71(4):693-702. PubMed ID: 28639112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.
    Munkarah AR; Genhai Z; Morris R; Baker VV; Deppe G; Diamond MP; Saed GM
    Gynecol Oncol; 2003 Mar; 88(3):429-33. PubMed ID: 12648598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
    Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
    J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.